Press Releases

April 13, 2017

DS Biopharma receives a patent allowance for Oral DS107 in the US

Dublin, Ireland, April 13th, 2017 – DS Biopharma (DS), a clinical stage biopharmaceutical company, today announced receipt of allowance for a patent application in the United […]
February 7, 2017

DS Biopharma appoints Jane Hollingsworth as Non-Executive Director

Dublin, Ireland, February 7, 2017 – DS Biopharma (DS), a clinical stage biopharmaceutical company, today announced the appointment of Jane Hollingsworth as a non-executive director to […]
January 6, 2017

DS Biopharma (DS) announces that recruitment has begun in two separate Phase 2b atopic dermatitis studies with lead compound DS107 as well as the successful completion of a Phase 1 trial for follow on compound DS109

Dublin, Ireland, 6th January, 2017: DS Biopharma (DS), a privately held, clinical stage, pharmaceutical drug discovery and development company, today announced that recruitment has begun in […]
November 28, 2016

DS Biopharma to present at Piper Jaffray 28th Annual Healthcare Conference

Dublin, Ireland, 28th November, 2016: DS Biopharma (DS), a privately held drug discovery and development company, today announced that it will present an overview of the […]
September 29, 2016

DS Biopharma will today present data on a Phase IIa study at the European Academy of Dermatology and Venereology (EADV) Congress

Dublin, Ireland, 29th September 2016: DS Biopharma (DS) will today present data on their Phase IIa study with DS107 for the treatment of atopic dermatitis at […]
September 15, 2016

DS Biopharma announces the appointment of Dr. Markus Weissbach as Chief Operating Officer

Dublin, Ireland, 14th September 2016: DS Biopharma (DS) today announced the appointment of Dr. Markus Weissbach (MD, PhD) to Chief Operating Officer. Markus has been Medical […]
August 23, 2016

DS Biopharma (DS) Announces Spin-Out Company Focused on Fibrotic Conditions and Pulmonary Disorders

Dublin, Ireland, 22 August 2016: DS Biopharma (DS), a privately held drug discovery and development company with industry-leading expertise in lipid science, today announces the launch […]
January 7, 2016

DS Biopharma announces positive top-line Phase IIa trial results for DS107 as an oral treatment for moderate to severe atopic dermatitis

Dublin, Ireland, January 7th, 2016 – DS Biopharma (DS), a privately held biopharmaceutical company, today announced positive top-line results from a Phase IIa clinical trial of […]
September 25, 2015

DS Biopharma appoints Leopoldo Zambeletti as Non-Executive Director

Dublin, Ireland, September 25, 2015 – DS Biopharma, a privately held biopharmaceutical company, today announced the appointment of Leopoldo Zambeletti as a Non-Executive Director to the […]
May 14, 2015

DS Biopharma to present at UBS Global Healthcare Conference

Dublin, Ireland, 14 May, 2015: DS Biopharma (DS), a privately held drug discovery and development company, today announced that it will present at the UBS Global […]
March 20, 2015

DS Biopharma (DS) presents late-breaking news abstract on DS107 at the American Association of Dermatology (AAD) Annual Meeting

DS Biopharma (DS) presents late-breaking news abstract on DS107 at the American Association of Dermatology (AAD) Annual Meeting; “The effective and safe use of DS107 cream […]
July 28, 2014

DS107G-01 – Successful completion of Phase I Oral DGLA clinical trial

DS Biopharma finds that orally administered DGLA distributes well to the skin resulting in high dermal bioavailability. DS Biopharma, a privately held biopharmaceutical company, today announced […]
July 8, 2014

Positive Phase II Results for DS107E

DS Biopharma, a privately held biopharmaceutical company, have announced positive Phase II results for DS107E (DGLA cream), as a topical treatment for atopic dermatitis. This study was a […]
January 23, 2014

DS Biopharma Expands Board of Directors

DS Biopharma, a privately held biopharmaceutical company, today announced two non-executive director appointments to the company’s Board, Dr. John Devane and Mr. Alan Cooke. “We are […]
December 23, 2013

DS Biopharma Patented OTC Product Line

DS Biopharma Announces Notification of Patent Allowance for U.S. Application 13/906,673 Exclusivity to at Least 2033 for the Company’s Market Ready, Advanced OTC Skin Care Product […]